Cited 2 times since 2023 (1.4 per year) source: EuropePMC Journal of the American Heart Association, Volume 12, Issue 18, 13 2 2023, Pages e029216 Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial. Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG, ODYSSEY OUTCOMES Investigators